Issue Date: August 21, 2017 | Web Date: August 20, 2017
Contract services for biologics evolve
Approximately half the drugs in the pharmaceutical pipeline now are biologics, a statistic that reflects the drug industry’s shift in emphasis over the past two decades from small to large molecules. In that time, drug firms outsourced much of their small-molecule research, development, and manufacturing operations and invested heavily in biologics. The small-molecule drug services sector, meanwhile, consolidated to create a business populated by what is known as contract development and manufacturing organizations, or CDMOs.. . .
To view the rest of this content, please log in with your ACS ID.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society